event-trade登录编辑
PR Newswire All News ReleasesQwen · 实盘不做把握 3/10不做原因:无可交易标的
北京时间·🕒 发布 20:17:00·⟳ 抓取 20:17:52 +52s·⚡ 决策 09-01 20:23:46 +5m54s·55.8 天前

美敦力宣布约7亿美元战略投资港股私人手术机器人公司康诺思腾(Cornerstone Robotics),获得Sentire手术系统美国以外部分市场分销权

直接受益方Cornerstone Robotics为私人公司,无公开可交易证券;直接交易对手美敦力市值约1180亿美元,7亿美元投资仅占~0.6%,不构成短线催化;最可比上市公司微创机器人实为竞争对手而非受益方;天智航属不同细分赛道,传导极弱。案例库显示同日已作为美敦力FY27Q1财报一部分评估并判为不做。所有候选均无正期望交易机会。

📄 原文PR Newswire All News Releases↗ 原文
Cornerstone Robotics Announces Strategic Partnership with Medtronic to Expand Global Access to Robotic-assisted Surgery…
不做 美敦力(MDT.US)
7亿美元战略投资仅占美敦力约1180亿美元市值的~0.6%,对超大市值公司不构成短线催化;且案例库显示该事件已作为FY27Q1财报一部分被评估为不做
不做 微创机器人-B(02252.HK)
Sentire与微创机器人Toumai同属软组织腔镜手术机器人赛道,美敦力获得Sentire分销权实质增强竞争压力而非利好;行业验证效应不足以抵消竞争加剧;股价近5日已跌5.7%,趋势偏弱
不做 天智航(688277.SH)
天智航主营骨科手术机器人,与Sentire(软组织/普外/妇科/胸外/泌尿)属不同细分赛道,事件传导极弱,无正期望
不做 Cornerstone Robotics(康诺思腾)(N/A)
私人公司,未在任何交易所上市,无公开可交易证券
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

结论摘要

美敦力宣布约7亿美元战略投资私人手术机器人公司Cornerstone Robotics并获Sentire系统部分海外市场分销权。直接受益方为私人公司不可交易;美敦力市值约1180亿美元,7亿美元占比仅~0.6%,对超大市值公司无短线弹性;最可比上市标的微创机器人(02252.HK)与Sentire同属软组织腔镜机器人赛道,美敦力获得分销权实质增强竞争而非利好;天智航(688277.SH)属骨科机器人,赛道不同。案例库显示该事件已作为美敦力FY27Q1财报组成部分被评估为不做。综合判断无可交易正期望标的。

🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗

反向证据

  • 做多前查反向 · 来源 kb_search · 日期 2026-03-17 · 影响 weakens
    KB文章确认Cornerstone Robotics(康诺思腾)与微创机器人、美敦力Hugo同属软组织腔镜手术机器人赛道,美敦力获得Sentire分销权增强竞争而非利好微创机器人
    检索:微创机器人 美敦力 竞争 康诺思腾 Sentire 分销 原文 ↗
  • 做多前查反向 · 来源 search_case_library · 日期 2026-09-01 · 影响 supports
    案例库显示同日已有3条关于美敦力FY27Q1财报(含Cornerstone Robotics合作)的决策记录,均判为不做;该合作已作为财报事件一部分被评估
    检索:美敦力 FY27Q1 财报 Cornerstone Robotics 合作

先例如何影响了这次决策

对本次决策的影响:所有候选因结构性原因(私人公司不可交易、超大市值无弹性、竞争对手非受益方)被排除,先例研究不改变结论

方向:无可用先例

涨幅量级:无高相似先例可校准幅度

形态:无

工具执行结果 · 成功 9 · 降级 6 · 失败 0 · 取消 0
  1. search_processed_events 成功 stock_tools HTTP · 982 ms
    {"result": "search_processed_events:agent query=`cornerstone robotics medtronic partnership | cornerstone robotics sentire distribution | medtronic surgical robotics investment | 手术机器人 美敦力 战略合作`;结构化索引覆盖完整 72 小时;旧记录兼容扫描近 62.7/72 小时、2207 条本臂决策(完整),返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选,不能据此证明消息首发或不是重
  2. fetch_decision_experience 成功 stock_tools HTTP · 611 ms
    {
  3. normalize_ticker 成功 stock_tools HTTP · 716 ms
    未归一到唯一代码;请用 stock_quote 的 candidates 消歧,或直接给代码。
  4. stock_quote 降级 stock_tools HTTP · 2,026 ms
    取价失败: Futu returned no quote
  5. get_stock_profile 成功 stock_tools HTTP · 6,030 ms
    {"result": "查询「手术机器人」成分股失败: (2003, \"Can't connect to MySQL server on '192.168.31.176' (timed out)\")"}
  6. stock_quote 降级 stock_tools HTTP · 2,686 ms
    取价失败: Futu returned no quote
  7. stock_quote 成功 stock_tools HTTP · 1,270 ms
    匹配到多个,请从 candidates 里选对的那只,用它的 canonical 代码再调用一次 stock_quote 确认。
  8. kb_search 降级 stock_tools HTTP · 4,926 ms
    {
  9. stock_quote 降级 stock_tools HTTP · 1,304 ms
    取价失败: Futu returned no quote
  10. stock_quote 降级 stock_tools HTTP · 497 ms
    {
  11. kb_search 成功 stock_tools HTTP · 3,211 ms
    {
  12. price_snapshot 降级 stock_tools HTTP · 508 ms
    {
  13. kb_search 成功 stock_tools HTTP · 2,744 ms
    {
  14. search_case_library 成功 stock_tools HTTP · 335 ms
    {"result": "search_case_library「02252.HK,MDT.US」—— 与这些标的相关的自家决策案例(本页 8 条,该标的全历史相关记录共 59 条;ENTER 只按该标的自己的腿统计):\n◆ 02252.HK:相关历史决策 19 条 · 其中该标的 ENTER 4 条(21.1%) · 已结算 4 笔 · 胜率 75% · 中位 +1.36% · 均值 +2.13% ⚠️只有 4 笔,样本太薄,只能当线索不能当规律\n◆ MDT.US:相关历史决策 40 条 · 其中该标的 ENTER 1 条(2.5%) · 已结算 1 笔 · 胜率 100% · 中位 +1
  15. kb_fetch_document 成功 stock_tools HTTP · 339 ms
    {

原文全文

展开原文 · 5,595 字
Cornerstone Robotics Announces Strategic Partnership with Medtronic to Expand Global Access to Robotic-assisted Surgery
HONG KONG, Sept. 1, 2026 /PRNewswire/ -- Cornerstone Robotics, an innovative surgical robotics company founded and headquartered in Hong Kong, today announced a strategic partnership with Medtronic (NYSE: MDT), a global leader in healthcare technology. As part of the partnership, Medtronic will make an approximately US$700 million strategic investment in Cornerstone Robotics and have rights to distribute Cornerstone Robotics' Sentire™ surgical system in select markets outside the U.S. where the system is market approved.
A Shared Vision: Bridging the Global Access Gap in Minimally Invasive Care
With robotic-assisted surgery adoption still in single digits globally, the opportunity to make advanced surgical care accessible to more patients, physicians, and health systems around the world is significant.
Addressing this market requires both continuous technical innovation and strong market scaling capabilities. By aligning Cornerstone Robotics' technology with Medtronic's comprehensive global presence, the two companies aim to make high-quality robotic-assisted surgery accessible to more patients worldwide.
A Strategic Alignment: Scaling Technology Solutions to Reach More Patients
Cornerstone Robotics has established a strong strategic foundation through its full-stack in-house R&D and vertically integrated paradigm. By independently developing its core hardware, control software, advanced algorithms, and proprietary imaging and energy platforms, Cornerstone Robotics maintains substantial control over product integration, quality, and supply chain resilience. This underpins the exceptional stability and high-fidelity performance of the Sentire surgical system in demanding clinical environments.
In 2024, Cornerstone Robotics' Sentire surgical system received National Medical Products Administration approval in China. In May 2026, Sentire surgical system received CE Mark in the European Union and approval from Singapore Health Sciences Authority, both covering minimally invasive general, gynecologic, thoracic, and urologic surgical procedures.
"This partnership marks an important step in advancing access to robotic-assisted surgery around the world," said Professor Kwok Wai Samuel AU, Founder and CEO of Cornerstone Robotics. "There remains a significant gap between the growing demand for minimally invasive surgery and the availability of robotic-assisted surgical technologies. At Cornerstone Robotics, we have built a strong foundation through full-stack in-house R&D and vertical integration, enabling us to continuously advance the core technologies of surgical robotics. Our partnership with Medtronic positions us to further accelerate and scale our work to bring the benefits of robotic-assisted surgery to more surgeons and patients around the world."
"This investment and distribution agreement strengthens Medtronic's ability to further expand access to minimally invasive surgery to more patients around the world. We're excited to bring more choice in robotics, and Sentire is a strong complement to our Hugo platform," said Matt Anderson, Senior Vice President and President, Surgical at Medtronic.
The partnership marks a significant milestone for both companies to collaboratively advance their shared mission of making robotic-assisted surgery more accessible worldwide.
Advisors
Kirkland & Ellis and Global Law Office are acting as legal counsel to Cornerstone Robotics. Morgan Stanley & Co. LLC is serving as exclusive financial advisor to Medtronic, and Cleary Gottlieb Steen & Hamilton LLP is serving as lead legal counsel.
About Cornerstone Robotics
Founded and headquartered in Hong Kong, Cornerstone Robotics is an innovative surgical robotics company driven by the vision of leading medical innovations for a healthier world. We advance surgical care with cutting-edge robotic systems that make high-quality healthcare more accessible and efficient globally. With three global R&D hubs and six business centres worldwide, Cornerstone Robotics has established a 30,000-square-meter manufacturing facility in China. Developed entirely in-house, our Sentire™ surgical system has completed multi-specialty clinical trials and received market approval across China, the European Union and Singapore, advancing high-quality surgical care worldwide.
To find out more information, please visit https://en.csrbtx.com/ and follow us on LinkedIn.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。